MedBright AI Investments Stock (OTC: MBAIF)

MedBright AI Investments (OTC:MBAIF) Stock, Quote.Headers.trade-ideas

MedBright AI Investments Inc is a capital allocator focusing on investing in healthcare technology companies.

MedBright AI Is Racing To Fix A $200 Billion Healthcare Problem

Penny Stocks

Health Care

General

MBAIF

CSE:MBAI

One of the most frustrating, time-consuming issues millions of patients have with their physicians is the waiting room. 

You may an appointment for a specific time, often told to show up about 15 minutes earlier than scheduled for paperwork. Then, you wait, watching the clock, questioning why you showed up early in the first place. 

MEDBRIGHT AI INVTS INC by MEDBRIGHT AI INVTS INC.

MedBright AI Investments Inc

JinkoSolar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) shares are trading higher Monday following the company&#8217;s announcement of a patent infringement lawsuit filed against VSUN Solar USA, Toyo Co. and their affiliates. Here&#8217;s<a href="https://www.benzinga.com/quote/JKS/news"> what you need to know.</a>
What To Know: The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges infringement of JinkoSolar's proprietary N-type TOPCon technology patents.
JinkoSolar, one of the world's leading solar module manufacturers, has an extensive intellectual property portfolio with over 2,800 patents, including 462 related to its TOPCon technology. The company emphasizes its commitment to protecting its innovations, which are a result of significant investments in research and development.
The lawsuit underscores JinkoSolar&#8217;s efforts to defend its position in the solar module market against competitors selling products that allegedly violate its patents. The company&#8217;s legal representation has stated that JinkoSolar intends to vigorously pursue its claims.
&#8220;JinkoSolar has earned its leadership position in the global solar module market through significant R&amp;D investments and will vigorously defend its intellectual property against those who sell infringing products,&#8221; said&nbsp;Louise Lu, a patent litigation lawyer with the Perkins Coie law firm.
JKS Price Action: JinkoSolar shares closed Monday up 6.77% at $28.70 at publication, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09154306/JKS-1024x530.png" alt="" class="wp-image-683959" style="width:492px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09154306/JKS-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09154306/JKS-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09154306/JKS-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09154306/JKS.png 1170w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42399235/bitcoin-ethereum-dogecoin-turn-red-timeline-got-bearish-trader-notes">Bitcoin, Ethereum, Dogecoin Turn Red: &#8216;Timeline Got Bearish,&#8217; Trader Notes</a></li>
</ul>
Photo: Shutterstock.

News

Legal

Movers

JinkoSolar Shares Are On The Rise Today: What's Going On?

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="580" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213417/Top-Image-1024x580.jpg" alt="" class="wp-image-3926" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213417/Top-Image-1024x580.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213417/Top-Image-300x170.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213417/Top-Image-768x435.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213417/Top-Image.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Overcoming A 44%+ Drop In A Top Stock</h2>
We&#8217;ve done well with Super Micro Computer (SMCI) recently, buying it at $21.86 last month (&#8220;<a href="https://www.benzinga.com/markets/24/11/42052075/turning-bullish-on-supermicro">Turning Bullish On Supermicro</a>&#8220;), and seeing the stock more than double since. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="955" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213503/SMCI-Monday-955x1024.jpg" alt="" class="wp-image-3927" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213503/SMCI-Monday-955x1024.jpg 955w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213503/SMCI-Monday-280x300.jpg 280w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213503/SMCI-Monday-768x824.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09213503/SMCI-Monday.jpg 1119w" sizes="(max-width: 955px) 100vw, 955px" /></figure>
But SMCI was in some of our hedged portfolios created six months ago, and it dropped more than 44% over that time frame.&nbsp;
Here&#8217;s a look at one of those portfolios, and how hedging and security selection enabled it to still smoke the S&amp;P 500.&nbsp;
<h2 class="wp-block-heading">Our Hedged Portfolio From June 6th, 2024</h2>
This was the hedged portfolio our system created on June 6th, for an investor with $3,000,000 to put to work who didn&#8217;t want to risk a decline of more than 30% over the next six months. Our system started by dividing the money in seven equal parts, and allocating it to&nbsp;Abercrombie &amp; Fitch Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>),&nbsp;Century Aluminum Co.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>)&nbsp;Dell Technologies&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>),&nbsp;Comfort Systems USA, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>),&nbsp;Powell Industries, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>), and&nbsp;Semtech Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>), in addition to&nbsp;Super Micro Computer Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).&nbsp;
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="700" height="538" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214000/1-Chart-.jpg" alt="" class="wp-image-3928" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214000/1-Chart-.jpg 700w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214000/1-Chart--300x231.jpg 300w" sizes="(max-width: 700px) 100vw, 700px" /></figure>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="700" height="646" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214220/2-Chart-1.jpg" alt="" class="wp-image-3930" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214220/2-Chart-1.jpg 700w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214220/2-Chart-1-300x277.jpg 300w" sizes="(max-width: 700px) 100vw, 700px" /></figure>
Screen captures via&nbsp;<a href="https://portfolioarmor.com/">Portfolio Armor</a>&nbsp;on 6/6/2024.
Next, it rounded down those seven dollar amounts to round lots of each of those names and their optimal hedges. Then it swept most of the leftover cash from that process into a tightly collared position in MicroStrategy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>). 
The dollar amount of the SMCI position (circled in red in the image above) at the start was $233,376 in underlying shares and $21,900 in puts for a total position value of $255,276. We&#8217;ll come back to that in a moment.&nbsp;
<h2 class="wp-block-heading">How That Portfolio Performed Over The Next 6 Months</h2>
Over the next six months, our portfolio was up 30.52%, net of hedging and trading costs, while the&nbsp;SPDR S&amp;P 500 Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 14.4%. So it more than doubled the performance of the market, despite SMCI dropping 44%.&nbsp;
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="700" height="545" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214404/1-Portfolio-.jpg" alt="" class="wp-image-3931" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214404/1-Portfolio-.jpg 700w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214404/1-Portfolio--300x234.jpg 300w" sizes="(max-width: 700px) 100vw, 700px" /></figure>
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="700" height="282" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214442/2-Portfolio.jpg" alt="" class="wp-image-3932" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214442/2-Portfolio.jpg 700w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09214442/2-Portfolio-300x121.jpg 300w" sizes="(max-width: 700px) 100vw, 700px" /></figure>
You can view an interactive version of the chart above <a href="https://portfolioarmor.com/front_tests/5769" target="_blank" rel="noreferrer noopener nofollow">here</a>.
You can see the ending value for the $SMCI plus its put hedge circled in red above: $202,155.30. Recall that the starting value for that position was&nbsp;$255,276. $202,155.30 represents a 20.8% drop from $255,276.&nbsp;
<h2 class="wp-block-heading">How This Portfolio Beat The Market Despite SMCI&#8217;s 44% Drop&nbsp;</h2>
We mentioned two reasons above: hedging and security selection. Both are true, but there&#8217;s a bit more to it.&nbsp;
<ul>
<li>Although SMCI dropped by 44%&#8211;and its hedge was designed to protect against a &gt;30% drop&#8211;it nevertheless limited the drawdown to 20.8%. That was due to the positive hedging error inherent in our hedging algorithm.&nbsp;</li>
<li>Security selection helped overall here in picking mostly winners. POWL, for example, was up more than 73% over that six-month period.&nbsp;</li>
<li>Concentration helped here too. Since there were only 8 underlying securities in the portfolio, the 73% gain in POWL had a big impact.&nbsp;</li>
<li>Finally, knowing when to hedge with optimal puts rather than optimal collars was key. Our system has an algorithm to determine that, and since it hedged POWL with puts, we captured nearly all of its upside.&nbsp;</li>
</ul>
You can use our system to create hedged portfolios for dollar amounts as small as $30,000&#8211;you just need to enter the dollar amount you want to invest and largest drawdown you&#8217;re willing to risk, and our system does the rest.&nbsp;
<h2 class="wp-block-heading">If You Just Want To Hedge What You Already Have</h2>
If you are concerned about downside risk, as a reminder, you can download our iPhone hedging app by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone).&nbsp;
<figure class="wp-block-image size-full"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09215017/QR-Code-2.jpg" alt="" class="wp-image-3933" /></a></figure>
And if you would like a heads up next time we place an aggressive trade, like our recent winner on QIFU Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) 
<ol>
<li>Calls on QIFU Technologies ( QFIN 2.17%↑). Bought at $2.15 on 10/1/2024; sold (half) at $6.45 on 12/9/2024. Profit: 200%.</li>
</ol>
You can subscribe to our trading Substack/occasional email list below.&nbsp;

If you&#8217;d like to stay in touch
You can scan for optimal hedges, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>. Or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09215518/Widget-2.jpg" alt="" class="wp-image-3934" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09215518/Widget-2.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09215518/Widget-2-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

Options

Trading Ideas

CENX

DELL

MSTR

POWL

QFIN

SMCI

SMTC

How To Beat The Market When One Of Your Top Stocks Drops 44%

OTTR

Otter Tail Power Plans To Add Two Solar Facilities To Its Energy Generation Fleet To Meet Customers' Future Energy Needs

ATSG

Air Transport Services Reports Expiration Of "Go-Shop" Period; Stonepeak Transaction To Close in H1 Of 2025

The Multidisciplinary Association for Psychedelic Studies (MAPS) introduced "Music is the Bridge," a new campaign that combines artist-curated playlists with free <a href="https://www.benzinga.com/markets/psychedelics">psychedelic education. </a>
Starting Monday, the project aims to make psychedelic experiences safer, more accessible and more meaningful.
<h3 class="wp-block-heading">Playlists From Artists And Organizations</h3>
The campaign includes playlists from artists and organizations like Lil Yachty, Melissa Etheridge, Brandon Boyd, Reggie Watts, CloZee, Boreta, Superposition, Good Trip Studios, East Forest, Dr. Bronner's as well as MAPS founder and president Rick Doblin aka "DJ Doblin."
See Also: <a href="https://www.benzinga.com/24/12/42394033/first-study-to-explore-psychedelics-and-sexual-health-shows-promising-results">Sexual Health: Psychedelics Found To Enhance Function In Imperial College Study</a>
Each playlist enhances different aspects of the psychedelic experience, from the journey itself to moments of reflection and integration.
"Music is medicine. This is something that cultures around the world have long known,&#8221; said Etheridge in a press release. &#8220;And in combination with plant medicines or psychedelics, they amplify one another, opening up a powerful journey to feel deeply and find truths."
GRAMMY-nominated Lil Yachty added, "Whenever I take a trip, I often spend the end of it reflecting and integrating my experiences—trying to understand why certain things are happening, what I'm doing well, and whether there's anything I could be doing differently."
<h3 class="wp-block-heading">Lead Singer Of Incubus</h3>
"Music and psychedelics have a partnership, a commingling that stretches back into prehistory," said Brandon Boyd of Incubus. "We could almost suggest that one wouldn't exist without the other in certain creative circles. I know with great certainty that psychedelics, predominantly psilocybin, have been deeply impactful to me in my experience as a younger man but also as I continue my creative pursuits as an adult. They are like a gift from God put here to offer access to other worlds, and a happy byproduct of that "access" is the music we hear along the way." Boreta, formerly of Glitch Mob, added: &#8220;My relationship with music and life is shaped by psychedelics, which have revealed the transformative power of sound and helped me connect with something larger than us all.&#8221;
<a href="https://www.benzinga.com/markets/cannabis/24/09/40823224/multidisciplinary-association-for-psychedelic-studies-eyes-state-level-legalization-after-fda-de">MAPS</a> plans to release new playlists each month as part of the campaign.
<h3 class="wp-block-heading">Free Psychedelic Education</h3>
In addition to the playlists, MAPS is offering a free course &#8220;Psychedelic Fundamentals,&#8221; which covers the basics of history, science, therapeutic uses and safety.
Normally priced at $29, the course takes only a few hours to complete. It provides key information for safe exploration, with a broad overview of the most interesting and important aspects of psychedelic history, science, clinical research, therapeutic uses and harm reduction.
Participants also get the MAPS Integration Station workbook, which helps them process and learn from their psychedelic experiences.
<h3 class="wp-block-heading">Join The Conversation</h3>
MAPS encourages people to share their favorite playlists on social media using the hashtag #MusicIsTheBridge. The campaign also features exclusive merchandise, including a commemorative T-shirt, available through the MAPS store.
For more details, playlists and educational resources, visit MAPS&#8217; website.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42346427/mapping-how-ayahuasca-affects-fear-circuits-key-insights-from-new-research">Mapping How Ayahuasca Affects Fear Circuits: Key Insights From New Research</a></li>
</ul>
Cover image made with AI.

Cannabis

Psychedelics

Education

Markets

MAPS Drops Free Psychedelic Education And Artist-Curated Playlists - Start Your Journey Here

REC-617 was generally well-tolerated across all dose levels, with no discontinuations due to adverse events (AEs). Adverse events to date were predominately Grade 1-2, on-target, and reversible. An MTD has not yet been reached.
REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement.
 &nbsp;
 &nbsp;

RXRX

Recursion ReportsInitial Monotherapy Dose-escalation Data From Phase 1/2 Study Of REC-617 In Advanced Solid Tumors

Paula G. O'Connor, M.D., chief medical officer of Nurix, said, "These positive results are particularly impressive given the inclusion of patients with a high incidence of baseline genetic mutations in BTK, PLCG2, and TP53, and challenging clinical factors, such as central nervous system involvement, which are associated with poor prognosis. We continue to enroll patients in the United States, the United Kingdom, and Europe in the Phase 1b portion of the trial and are on track to initiate pivotal trials of NX-5948 in 2025."

NRIX

Nurix Therapeutics Presents New Clinical Data From Patients With Relapsed Or Refractory CLL/SLL Treated In  Phase 1a/1b Clinical Trial Of Its Bruton's Tyrosine Kinase Degrader NX-5948

Offerings

MAIA

MAIA Biotechnology Enters Definitive Agreements For Purchase And Sale Of Aggregate 507,364 Shares Of Common Stock At $1.872 Per Share, In Private Placement

THE STOCK ROSE 6.5% FRO THE SIGNAL
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="689" height="611" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09210904/Screen-Shot-2024-12-09-at-4.07.08-PM.png" alt="" class="wp-image-3923" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09210904/Screen-Shot-2024-12-09-at-4.07.08-PM.png 689w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/12/09210904/Screen-Shot-2024-12-09-at-4.07.08-PM-300x266.png 300w" sizes="(max-width: 689px) 100vw, 689px" /></figure>
Applovin corp, (APP) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
At 10:36 AM on December 9th, a significant trading signal occurred for Applovin corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) as it demonstrated a Power Inflow at a price of $336.87. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Applovin&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Applovin&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for APP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $336.87. The returns on the High ($358.72)&nbsp;and Close ($342.53)&nbsp;after the Power Inflow were&nbsp;6.5% and 1.2%, respectively. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. 
Past Performance is Not Indicative of Future Results

TradePulse Power Inflow Alert: Applovin (APP) Receives Alert After Dropping Early, Then Rises Over 20 Points

SSNC

SS&C Enters An Initial Agreement With Insignia Financial To Deliver Superannuation Member Administration Services

The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long-term survival. The data were shared in an oral presentation (Abstract #864) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
"There is growing evidence that people with follicular lymphoma and marginal zone lymphoma can experience long-term survival after one Yescarta treatment," said Dominique Tonelli, VP, Global Head of Medical Affairs, Kite. "With no lymphoma-specific events in the five-year follow-up of ZUMA-5 patients, Yescarta may offer patients the chance to live longer without need for subsequent therapy and a potential cure."

GILD

Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta

Multiple analyses underscore durable efficacy and well-established safety profile of Breyanzi (lisocabtagene maraleucel; liso-cel) in leukemia and several types of lymphoma.
 &nbsp;

Bristol Myers Squibb Reports Results From 18 Presentations; Data Demonstrate Efficacy, Durability And Safety Of Currently Available Therapies In Blood Cancers

Nio Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares gained 12.36% to $5.18 on Monday. Shares of U.S.-listed Chinese stock traded higher following reports suggesting Chinese officials would embrace a &#8220;moderately loose&#8221; monetary policy ahead of China's Central Economic Work Conference. 
What To Know: This key policy meeting, expected to outline economic strategies for 2025, has fueled optimism among investors, particularly after the Politburo, led by President Xi Jinping, pledged <a href="https://www.benzinga.com/government/regulations/24/12/42391254/us-listed-chinese-stocks-jump-on-chinas-stimulus-measures-looser-monetary-policy-assurances">"more proactive"</a> fiscal measures and "moderately" looser monetary policies to stimulate domestic consumption and stabilize key markets.
Nio is well-positioned to benefit from these measures, as the EV industry is a cornerstone of China's push for sustainable economic growth. Government support for clean energy and advanced technology sectors is expected to create tailwinds for Nio's operations.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/12/42400723/oracle-q2-earnings-revenue-miss-eps-miss-ai-growth-ellison-says-opportunity-is-unimaginable">Oracle Q2 Earnings: Revenue Miss, EPS Miss, AI Growth, Ellison Says &#8216;Opportunity Is Unimaginable&#8217;</a>
Policies promoting infrastructure development and increased consumer spending could further drive demand for premium electric vehicles, a segment where NIO has built a strong brand presence.
Additionally, potential interest rate cuts and fiscal expansion could reduce borrowing costs for Nio, enabling the company to invest in innovation and scale production. This is especially critical as Nio continues to expand its product lineup and charging infrastructure.&nbsp;
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Nio has a 52-week high of $9.57 and a 52-week low of $3.61. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42360675/nvidia-could-become-taiwan-semis-third-us-plant-customer-but-with-a-catch" target="_blank" rel="noreferrer noopener">Nvidia Could Become Taiwan Semi's Third US Plant Customer, But With A Catch</a></li>
</ul>
Photo: Sundry Photography on Shutterstock

Global

What's Going On With NIO Stock Today?

The study's primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR), based on independent review committee (IRC) assessment.
Today's updated results&nbsp;corresponding to the final prespecified analysis, demonstrate consistent improvement in PFS for patients treated with pirtobrutinib, with a reduction in risk of relapse, disease or death by&nbsp;46% compared to IdelaR or BR.&nbsp;
Pirtobrutinib also demonstrated clinically meaningful improvements in other secondary endpoints such as investigator-assessed PFS (median PFS: 15.3 vs. 9.2 months.

Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis

TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is highly encouraged by the preliminary ALLOHA study results, which suggest that TSC-100 and TSC-101 have the potential to eliminate residual disease and prevent relapse in patients with AML, ALL, or MDS post-HCT.

TCRX

TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting

The Company has determined that its previously issued consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 and the related management's discussion and analysis for the year ended December 31, 2023, as well as the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2024 and 2023 and the related management's discussion and analysis for the three and nine months ended September 30, 2024, should be restated to correct a material error in the classification of proceeds derived from the sale of digital assets.

BITF

Bitfarms Reveals Restatement Of Certain Previously Issued Financial Statements

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial.
 Primary analysis from an expansion cohort of the ELM-1 trial highlighted continued efficacy and durability in diffuse large B-cell lymphoma patients whose disease had progressed after CAR-T therapy.
 First results from the ELM-2 trial in marginal zone lymphoma demonstrated high complete response rate in patients with relapsed/refractory disease. &nbsp;

REGN

Regeneron Presents New And Updated Data For Odronextamab At ASH Annual Meeting

A proposal by Donald Trump to impose tariffs on products that come to the U.S. from China, Canada and Mexico could have an impact on products and their prices found in<a href="https://www.benzinga.com/24/12/42291861/trumps-tariff-plan-risks-economic-pain-for-north-america-goldman-sachs-warns"> American dollar stores.</a>
What Happened: For years, dollar stores have offered items across their aisles that cost $1 or less in many cases. That has changed over the years with dollar stores owned by Dollar Tree Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) <a href="https://www.benzinga.com/news/earnings/21/11/24262913/is-dollar-tree-becoming-the-1-25-store-heres-what-investors-and-shoppers-should-know">raising prices to $1.25</a> to offset higher inflation.
Trump's tariff plans could mean further price hikes in Dollar Tree stores or changes to the product assortment, according to company officials.
"While the situation remains fluid and the exact nature, scope, and eventual timing of any new tariffs is not yet clear, we are prepared to act on multiple fronts," Dollar Tree Chief Operating Officer and Interim CEO Mike Creedon said on Dollar Tree's <a href="https://www.benzinga.com/apis/cloud-product/conference-call-transcripts/">recent conference call.</a>
Creedon said Dollar Tree was able to negotiate lower costs with suppliers back in 2018 and 2019 when last dealing with tariff concerns. The company also changed product specs and pack sizes along with stopping the sale of several items altogether.
"All three of those options are still at our disposal."
The Dollar Tree interim CEO also said the company is working on supply sources from alternate countries.
"We believe there is a wide range of potential actions that we can take to help mitigate additional tariffs if and when they materialize."
Creedon said the company's multi-price strategy, which includes items past the $1 and $1.25 price points, could also be a solution for the tariff plans when asked to share what the downside case to the company's earnings is due to tariffs.
"Multi-price gives us the ability to flex where we need to if a certain product becomes something that we've got to move in the market to be competitive."
Read Also: <a href="https://www.benzinga.com/news/global/24/12/42300450/trump-told-trudeau-canada-could-avoid-tariffs-by-becoming-51st-state-a-look-at-sectors-trade-war-could-impact">Trump Told Trudeau Canada Could Dodge Tariffs As 51st State: Which Sectors Could Be Hit</a>
Why It's Important: Plans call for 25% tariffs on products imported from Mexico and Canada and 10% tariffs on products imported from China.
Retailers who sell consumer products could see higher costs for items they sell in the store. Companies will be tasked with deciding how to maintain their pricing power from suppliers, keeping prices the same and hurting their own profit margins or passing the higher costs onto consumers.
Based on the commentary from Dollar Tree, the company plans on a combination of both trying to lower costs from suppliers and raising prices for consumers.
Similar to fighting off inflation, Dollar Tree and other retailers could also look to change product size and assortment to keep prices the same for consumers or eliminate some items that aren't as profitable and perhaps also not as in demand from consumers.
Dollar Tree <a href="https://www.benzinga.com/24/12/42314941/dollar-tree-boosts-annual-profit-outlook-as-q3-earnings-surpass-expectations-stock-jumps">reported third-quarter </a>revenue and earnings per share that beat analyst estimates along with a better outlook for the full fiscal year. The company received several <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">price target hikes</a> from analysts after the report. 
DLTR Price Action: Dollar Tree stock closed down 0.38% to $71.60 on Monday versus a 52-week trading range of $60.49 to $151.22. Dollar Tree stock is down 50% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42220682/trump-tariffs-on-mexico-could-affect-beer-why-your-modelo-corona-could-cost-more-next-year">Trump Tariffs On Mexico Could Affect Beer: Why Your Modelo, Corona Could Cost More Next Year</a></li>
</ul>
Photo: Jonathan Weiss via Shutterstock

Politics

Economics

DLTR

Trump To Change Dollar Stores For Good? Dollar Tree Exec Says 'Prepared To Act'

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) has outperformed the market over the past 5 years by 17.36% on an annualized basis producing an average annual return of 31.13%. Currently, Pure Storage has a market capitalization of $20.97 billion. 
Buying $100 In PSTG: If an investor had bought $100 of PSTG stock 5 years ago, it would be worth $386.96 today based on a price of $64.00 for PSTG at the time of writing.
<h3>Pure Storage's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733783416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PSTG

Here's How Much You Would Have Made Owning Pure Storage Stock In The Last 5 Years

Guidance

ORCL

Oracle Expects Q3 Revenue To Grow 9% - 11%, Adj. EPS To Be $1.50 - $1.54 (Est $1.57)

MedBright AI appoints Trevor Vieweg as its CEO

MedBright AI reaches $100M in total clinic revenue under contract with Medmatrix

MedMatrix go-to-market pricing announced for AI product suite addressing $726B market

MedBright signs three-year contract for its AI platform with Southern California clinic

Press Releases

Global Education Communities Corp. Reports Normal Course Issuer Bid

Earnings

Global Education Communities Corp. Reports Fiscal 2024 Second Quarter Financial Results

Contracts

Southern California Clinic Signs Multi-Year Deal for MedMatrix AI Platform

Global Education Communities Corp. Formally Adds GEC Kingsway to Its Portfolio

MedBright AI Announces New Commercial Product Demos for MedMatrix AI Platform

Global Education Communities Corp. Provides Update on GEC Viva

GECC Provides Updates on its Corporate Activities

MedBright AI Announces Strategic Acquisition by Numinus Wellness

MedBright AI Issues Clarifying News Release on Continuous Disclosure Record

Management

MedBright AI Announces the Appointment of Christopher Heath as CEO and Termination of Letter of Intent

Comments

MedBright AI Investments

MedBright AI Investments (MBAIF) Forecast

MedBright AI Investments (OTC:MBAIF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga